Choice of chemotherapy in patients with lung cancer

In recent years, the incidence of lung cancer increased year by year, for various reasons, patients with lung cancer at the time of diagnosis, most of them have varying degrees of transfer, lost the opportunity to surgery, although some patients also made surgery, but soon in the lungs or other parts there metastases. So lung cancer chemotherapy (hereinafter referred to chemotherapy) as a systemic treatment methods, the importance of more and more attention. Patients with lung cancer chemotherapy how to choose them?

First, acute symptoms, relief permanent, partial body combine. Patients with lung cancer in accordance with clinical symptoms of systemic conditions and choose a different chemotherapy, if serious, such as dyspnea or hemoptysis symptoms, to be used in interventional chemotherapy, that is, select bronchial artery or pulmonary artery catheterization treatment; if there is a large number of the pleural effusion, thoracic drainage should be taken of the chest cavity after local chemotherapy, but an improvement in symptoms or the time of diagnosis has been widely lesions or bone, brain, lung and other distant metastasis, and should be the preferred intravenous systemic chemotherapy. Even if only a relatively limited tumor must also be added to systemic chemotherapy, because of distant metastasis of lung cancer is more common, is a systemic chemotherapy to prevent an effective means of tumor metastasis.

Second, treatment must be standardized, after clean-up is essential. After a lot of patients with lung cancer tumor after chemotherapy significantly reduced, or even disappear, but soon they recurrence or metastasis, one of the reasons is lack of standardized treatment. Squamata type of lung cancer, glandular and small cell undifferentiated type, such as the cytology. Clinical stages have different drug programs, methods and treatment of chemotherapy also varied, so must be given standardized treatment. Generally speaking, small cell lung cancer as a result of a vicious high degree of early distant metastasis, it is necessary to maximize the use of the entire table clock chemotherapy, duration of treatment longer. Scales adenocarcinoma give more consideration to local chemotherapy, treatments may be some shorter. Lung cancer patients may be due to the existence of the body have been found tiny metastases, it is only prudent, it should be a "cleaning" of systemic chemotherapy to destruction of residual cancer cells in vivo, as patients in phases, Phase Ⅱ above, after the need for chemotherapy, time after 3-4 weeks is appropriate, methods, and treatment according to different cell types and stages of the.

Third, the combination of immunochemotherapy, biological missile good effect. Because chemotherapy drugs have greater toxicity, and some interventional treatment such as chemotherapy, such as a certain traumatic. So that the use of chemotherapy subject to certain restrictions. And immunization and chemotherapy combination of methods, that is, monoclonal antibody (referred to as monoclonal antibody) and the whole knot of anti-cancer drug therapy to make up for the shortage, greatly widened the road of anti-cancer treatment. As the monoclonal antibody with a specific direction, it is known as biological missile after it enters the body through the tumor tissue, when its linked to drugs or radioactive substances (known as warheads) and vector (mAb) generated after the separation of cancer cells killing off specific role, and very little of normal tissue injury, can significantly improve the efficacy and reduce side effects of chemotherapy.